Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a randomize...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Urol
Main Authors: Hsieh, James J., Chen, David, Wang, Patricia I., Marker, Mahtab, Redzematovic, Almedina, Chen, Ying-Bei, Selcuklu, S. Duygu, Weinhold, Nils, Bouvier, Nancy, Huberman, Kety H., Bhanot, Umesh, Chevinsky, Michael S., Patel, Parul, Pinciroli, Patrizia, Won, Helen H., You, Daoqi, Viale, Agnes, Lee, William, Hakimi, A. Ari, Berger, Michael F., Socci, Nicholas D., Cheng, Emily H., Knox, Jennifer, Voss, Martin H., Voi, Maurizio, Motzer, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431298/
https://ncbi.nlm.nih.gov/pubmed/27751729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.10.007
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares